Arcellx, Inc. announced positive results from its December 6, 2025 press release regarding the Phase 2 iMMagine-1 study for its treatment of multiple myeloma, based on data from October 7, 2025.
AI Assistant
ARCELLX INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.